Alpha Tau Medical Ltd

DRTS

$14.46

Updated: 24/09/2026, 20:12:14

Market Cap

$1.31B

Sector

Healthcare

Industry

Biotechnology

Country

Stock valuation chart

One-year closing share-price history for DRTS

Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.

USD

NASDAQ

CEO: Uzi Sofer

Employees: 121

https://www.alphatau.com

Asset Summaries

Latest generated summaries for DRTS

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for DRTS.

Share price: $14.46
Market cap: $1.31B
Exchange: NASDAQ
Currency: USD
CEO: Uzi Sofer
Employees: 121
IPO date: 08/03/2021
Beta: 1.206
Last dividend: $0.00
Day range: $14.32 – $14.59
52-week range: $3.43 – $15.79
1-day performance: -0.41%
1-year performance: 321.57%
Current drawdown (1Y): -8.42%
CIK: 0001871321
CUSIP: M0740A108
ISIN: IL0011839383
Created: 07/12/2025, 03:38:50
Last update: 24/09/2026, 20:12:14

Track Alpha Tau Medical Ltd with an AI analyst

See which prediction-market events move DRTS, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to DRTS from your Railway `news_articles` table.

Alpha Tau Medical: A Lot Of Shots On Goal

Seeking Alpha • STOCK • 12/06/2026, 10:13:45

Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears

MarketBeat • STOCK • 29/05/2026, 11:04:16

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewsWire • STOCK • 18/05/2026, 18:01:00

Alpha Tau to Participate in May Investor Conferences

GlobeNewsWire • STOCK • 18/05/2026, 10:30:00

Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study

MarketBeat • STOCK • 11/05/2026, 12:09:01

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

GlobeNewsWire • STOCK • 08/05/2026, 11:10:00

Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies

GlobeNewsWire • STOCK • 27/04/2026, 11:01:00

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial

GlobeNewsWire • STOCK • 23/04/2026, 11:01:00

Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026

GlobeNewsWire • STOCK • 31/03/2026, 11:15:00

Alpha Tau Medical: 2026 Is The Breakthrough Year

Seeking Alpha • STOCK • 24/03/2026, 01:31:24

Alpha Tau to Present at Sidoti March Virtual Small Cap Conference

GlobeNewsWire • STOCK • 16/03/2026, 11:02:00

Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

GlobeNewsWire • STOCK • 09/03/2026, 17:02:00